National Institutes of Health Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain

September 29-30, 2014

Agenda

Monday, September 29, 2014

8:30 a.m. Welcome

Nora D. Volkow, M.D.

Director

National Institute on Drug Abuse National Institutes of Health

8:45 a.m. **Opening Remarks**

Story C. Landis, Ph.D.

Director

National Institute of Neurological Disorders and Stroke

National Institutes of Health

9:00 a.m. Charge to the Panel

David M. Murray, Ph.D.

Associate Director for Prevention

Director

Office of Disease Prevention

Division of Program Coordination, Planning, and Strategic Initiatives

Office of the Director

National Institutes of Health

9:10 a.m. Workshop Overview and Panel Activities

David B. Reuben, M.D.

Chief

Division of Geriatrics

Director

Multicampus Program in Geriatric Medicine and Gerontology

Professor of Medicine Division of Geriatrics

David Geffen School of Medicine at the University of California,

Los Angeles

9:20 a.m. Overview of Topic

David A. Thomas, Ph.D.

Deputy Director

Division of Clinical Neurosciences and Behavioral Research

National Institute on Drug Abuse National Institutes of Health

Attendees will be responsible for meals and/or light refreshments on their own, at their own expense. The government and/or government contractors are not involved in facilitating the provision of food and/or light refreshments.

Monday, September 29, 2014 (continued)

9:40 a.m. The Folly of Trying To Speak for the 100 Million Americans

Myra Christopher, L.H.D. (Hon.)

Kathleen M. Foley Chair for Pain and Palliative Care

Center for Practical Bioethics

10:00 a.m. Clinician Perspective

David J. Tauben, M.D. Clinical Associate Professor Department of Medicine

Chief (Interim)

Division of Pain Medicine

Medical Director Center for Pain Relief University of Washington

I. What is the long-term effectiveness of opioids?

10:20 a.m. Evidence-based Practice Center I: Overview of Systematic Review

Methodology and What Is the Long-Term Effectiveness of Opioids?

Roger Chou, M.D., FACP

Director

Pacific Northwest Evidence-based Practice Center

Professor of Medicine

Department of Medical Informatics & Clinical Epidemiology

Oregon Health & Science University

10:50 a.m. What Is The Long-Term Effectiveness of Opioids: Interpretation of

Evidence

Jane C. Ballantyne, M.D.

Professor, Retired

Department of Anesthesiology and Pain Medicine

University of Washington

11:10 a.m. Understanding the Data: Efficacy, Effectiveness, and Generalizability

Russell K. Portenoy, M.D.

Chief Medical Officer

Metropolitan Jewish Health System (MHJS) Hospice and Palliative Care

Director

MJHS Institute for Innovation in Palliative Care

Professor of Neurology

Albert Einstein College of Medicine

11:30 a.m. **Break**

Monday, September 29, 2014 (continued)

11:50 a.m. Predicting Individual Differences in Opioid Analgesic Effectiveness

Stephen Bruehl, Ph.D.

Professor

Department of Anesthesiology

Vanderbilt University School of Medicine

12:10 p.m. Are Opioids Preferentially Effective in Treating Different Underlying

Mechanisms of Chronic Pain?

Daniel J. Clauw, M.D.

Professor of Anesthesiology, Medicine and Psychiatry

Director

Chronic Pain and Fatigue Research Center University of Michigan Medical Center

12:30 p.m. Lunch (to be provided at the expense of the attendee)

1:30 p.m. **Discussion**

II. What are the safety and harms of opioids in patients with chronic pain?

2:20 p.m. Evidence-based Practice Center II: What Are the Safety and Harms of

Opioids in Patients With Chronic Pain?

Judith Turner, Ph.D.

Professor

Department of Psychiatry and Behavioral Sciences

University of Washington

2:40 p.m. Adverse Drug Reactions With Opioid Analgesic Use in Older Adults

Joseph T. Hanlon, Pharm.D., M.S.

Professor

Division of Geriatrics/Gerontology

Department of Medicine

University of Pittsburgh School of Medicine

3:00 p.m. **Prescription Opioids and Substance Use Disorder**

Edward C. Covington, M.D.

Director

Neurological Center for Pain

Cleveland Clinic

Monday, September 29, 2014 (continued)

3:20 p.m. Risks of Opioid Therapy

Nathaniel P. Katz, M.D., M.S.

President and Chief Executive Officer

Analgesic Solutions

Adjunct Assistant Professor of Anesthesia

Tufts University School of Medicine

3:40 p.m. **Public Health Impact**

Jane C. Maxwell, Ph.D. Senior Research Scientist Addiction Research Institute

University of Texas at Austin School of Social Work

4:00 p.m. **Discussion**

5:00 p.m. Adjourn

Tuesday, September 30, 2014

III. What are the effects of different opioid management strategies?

8:30 a.m. Evidence-based Practice Center Presentation III: What Are the Effects of Different Opioid Management Strategies?

Roger Chou, M.D., FACP

Director

Pacific Northwest Evidence-based Practice Center

Professor of Medicine

Department of Medical Informatics & Clinical Epidemiology

Oregon Health & Science University

8:50 a.m. Selected Strategies To Optimize Opioid Therapy and Decrease Risk of

Abuse:: State of the Evidence Ricardo A. Cruciani, M.D., Ph.D.

Director

Center for Comprehensive Pain Management and Palliative Care

Capital Institute for Neuroscience Capital Health Medical Center

9:10 a.m. Effectiveness of Treatment Strategies for Managing Patients With

Addiction to Prescription Opioids on Outcomes Related to Addiction,

Abuse, Misuse, Pain, Function, and Quality of Life

Steven D. Passik, Ph.D.

Vice President

Clinical Research and Advocacy Millennium Research Institute Millennium Laboratories

9:30 a.m. Impact of Pharmacokinetics and Pharmacodynamics: Relevance to Abuse and Addiction and Risks in Treatment

Sharon Walsh. Ph.D.

Professor of Behavioral Sciences, Psychiatry, Pharmacology, and

Pharmaceutical Science

Director

Center on Drug and Alcohol Research University of Kentucky College of Medicine

9:50 a.m. **Discussion**

Tuesday, September 30, 2014 (continued)

IV. What is the effectiveness of risk mitigation strategies for opioid treatment?

10:30 a.m. Evidence-based Practice Center IV: What Is the Effectiveness of Risk

Mitigation Strategies for Opioid Treatment?

Judith Turner, Ph.D.

Professor

Department of Psychiatry and Behavioral Sciences

University of Washington

10:50 a.m. Risk Mitigation by Way of Naloxone

Phillip O. Coffin, M.D., M.I.A.

Director of Substance Use Research

HIV Prevention Section

San Francisco Department of Public Health

11:10 a.m. Opioid Risk Mitigation and Adherence Monitoring in Practice

Erin E. Krebs, M.D., M.P.H.

Core Investigator

Center for Chronic Disease Outcomes Research

Medical Director

Women Veterans Comprehensive Health Center

Minneapolis Veterans Administration

Associate Professor Department of Medicine University of Minnesota

11:30 a.m. Prescription Opioid Misuse and Addiction: A National Priority

Wilson M. Compton, M.D., M.P.E.

Deputy Director

National Institute on Drug Abuse National Institutes of Health

11:50 a.m. **Discussion**

Tuesday, September 30, 2014 (continued)

12:30 p.m. **Break**

12:50 p.m. Roundtable Discussion on Opioids in the Real World

Wendy B. Smith, Ph.D., M.A., BCB, Moderator

Senior Scientific Advisor for Research Development and Outreach

Office of Behavioral and Social Sciences Research

Office of the Director

National Institutes of Health

Daniel J. Clauw, M.D., Panelist

Professor of Anesthesiology, Medicine and Psychiatry

Director

Chronic Pain and Fatigue Research Center

University of Michigan Medical Center

Ricardo A. Cruciani, M.D., Ph.D., Panelist

Director

Center for Comprehensive Pain Management and Palliative Care

Capital Institute for Neuroscience Capital Health Medical Center

Tracy W. Gaudet, M.D., Panelist

Director

Office of Patient Centered Care and Cultural Transformation

Veterans Health Administration U.S. Department of Veterans Affairs

1:30 p.m. Workshop Wrap-Up/Next Steps

1:40 p.m. **Adjourn**